Rheumatoid arthritis (RA) management still rests on methotrexate and biologic DMARDs, but the landscape has expanded to targeted oral JAK inhibitors, novel immune-checkpoint approaches, and — at the experimental edge — cell therapies for refractory disease. The story of the past few years is as much about safety and sequencing as about raw efficacy.
JAK inhibition: efficacy with a safety asterisk
In the Phase 3 SELECT-CHOICE trial in patients refractory to biologic DMARDs, the oral JAK inhibitor upadacitinib was superior to the T-cell costimulation blocker abatacept: greater reduction in DAS28-CRP (−2.52 vs −2.00) and higher clinical remission (30.0% vs 13.3%), with better pain and physical-function outcomes. But upadacitinib also carried more serious adverse events, and the whole JAK class now sits under a cloud cast by the ORAL Surveillance safety trial, which linked JAK inhibitors to higher rates of major cardiovascular events, malignancy, venous thromboembolism, and mortality relative to TNF inhibitors — particularly in patients over 50 with cardiovascular risk factors. This prompted class-wide boxed warnings, and real-world data show higher discontinuation for adverse events than with TNF- or IL-6-inhibitors despite similar effectiveness. JAK inhibitors remain valuable, but patient selection and risk stratification now matter more than ever.
Peresolimab: a novel immunoregulatory approach
Peresolimab takes the opposite tack from most RA drugs: rather than blocking an inflammatory pathway, it stimulates the inhibitory PD-1 checkpoint. In a Phase 2 trial, the 700-mg dose significantly reduced DAS28-CRP versus placebo (−2.09 vs −0.99), with a safety profile similar to placebo and no early signal of increased serious infection or malignancy. It is a genuinely new mechanism for refractory RA, though Phase 3 confirmation and longer follow-up are still needed.
Cell therapy at the frontier
The most striking experimental development is CD19-targeted CAR-T cell therapy, which, by deeply depleting B cells, has induced drug-free remission in small numbers of patients with refractory RA — part of a broader wave of CAR-T use across autoimmune disease. It remains costly, complex, and confined to case series, with long-term safety unknown, but it raises the prospect of an immune "reset" rather than indefinite suppression.
Alongside these, TNF and IL-6 inhibitors, rituximab, and an expanding roster of biosimilars continue to broaden access, with subcutaneous and oral formulations improving convenience.
| Therapy | Mechanism | Key result | Consideration |
|---|---|---|---|
| Upadacitinib | JAK1 inhibitor | Superior to abatacept (remission 30% vs 13%) | Class boxed warning (CV, malignancy, VTE) |
| Peresolimab | PD-1 agonist | Positive Phase 2 (DAS28-CRP) | Phase 3 awaited |
| TNF/IL-6 inhibitors | Biologic DMARDs | Effective; biosimilars expanding | Infection, injection reactions |
| CD19 CAR-T | B-cell depletion | Drug-free remission (case series) | Experimental; cost, safety unknown |
Further reading: SELECT-CHOICE (Rubbert-Roth et al., NEJM 2020); peresolimab Phase 2 (Tuttle et al., NEJM 2023); ORAL Surveillance and upadacitinib safety analyses (2021–2023); CAR-T in autoimmune disease (Müller et al., NEJM 2024).